Renalis develops prescription digital therapeutics For The treatment of pelvic health disorder. The first product is CeCe a mobile-enhanced digital therapeutic for first-line treatment of overactive bladder (OAB) in persons assigned female at birth. CeCe delivers cost-effective, accessible, and engaging behavioral therapy to patients with OAB symptoms via their smartphone or smart device.
UH Ventures invested in Renalis via the Healthcare Collaboration Fund, a fund co-managed with our partners at Jumpstart. The fund targets investments in Northeast Ohio technology startup companies primarily in the areas of biomedical and life sciences related to diagnostics, imaging, surgical instruments and equipment, implant devices, therapeutics, and regenerative medicine, as well as software applications for health care.